Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 4, 2011, Pages 274-284

  Andresen, Trine ^a,b   Upton, Richard N ^c   Foster, David J R ^c   Christrup, Lona L ^d   Arendt Nielsen, Lars ^b   Drewes, Asbjørn M ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CAPSAICIN; FENTANYL; NERVE GROWTH FACTOR; NORBUPRENORPHINE; NORSPAN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALLODYNIA; ANALGESIC ACTIVITY; ARTICLE; BLOOD SAMPLING; BONE PAIN; COLD PRESSOR TEST; CONCENTRATION RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HUMAN EXPERIMENT; HYPERALGESIA; MALE; NORMAL HUMAN; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERMAL STIMULATION; TIBIA;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; CAPSAICIN; COLD TEMPERATURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FENTANYL; HOT TEMPERATURE; HUMANS; HYPERALGESIA; MALE; MODELS, BIOLOGICAL; PAIN; PAIN MEASUREMENT; TIME FACTORS; TRANSDERMAL PATCH; YOUNG ADULT;

EID: 79952796063     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00649.x     Document Type: Article

References (40)

1. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009;13:219-30.
2. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 2006;13:175-87.
3. Yassen A, Olofsen E, Dahan A, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 2005;313:1136-49.
4. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005;29:297-326.
5. Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol 2009;5:230-41.
6. Suri A, Estes KS, Geisslinger G, Derendorf H. Pharmacokinetic-pharmacodynamic relationships for analgesics. Int J Clin Pharmacol Ther 1997;35:307-23.
7. Drewes AM, Schipper KP, Dimcevski G, Petersen P, Andersen OK, Gregersen H et al. Multi-modal induction and assessment of allodynia and hyperalgesia in the human oesophagus. Eur J Pain 2003;7:539-49.
8. Staahl C, Drewes AM. Experimental human pain models: a review of standardised methods for preclinical testing of analgesics. Basic Clin Pharmacol Toxicol 2004;95:97-111.
9. Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005;5(Suppl):S90-103.
10. Sittl R, Nuijten M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther 2005;27:1022-31.
11. Hamilton RC, Dundee JW, Clarke RS, Loan WB, Morrison JD. Alterations in response to somatic pain associated with anaesthesia. 18. Studies with some opiate antagonists. Br J Anaesth 1967;39:490-502.
12. Curatolo M, Petersen-Felix S, rendt-Nielsen L. Sensory assessment of regional analgesia in humans: a review of methods and applications. Anesthesiology 2000;93:1517-30.
13. Svensson P, Cairns BE, Wang K, Arendt-Nielsen L. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain 2003;2: 241-7.
14. Torebjork HE, Lundberg LE, LaMotte RH. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans. J Physiol 1992;448:765-80.
15. NONMEM User's Guides [computer program]. 2006.
16. Kass R, Raftery A. Bayes factors. J Am Stat 1995;90:773-95.
17. Olesen AE, Upton R, Foster D, Staahl C, Christrup L, Arendt-Nielsen L. et al. Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia. Clin Pharmacokinet 2010;49:817-27.
18. Hull CJ, Van Beem HB, McLeod K, Sibbald A, Watson MJ. A pharmacodynamic model for pancuronium. Br J Anaesth 1978;50:1113-23.
19. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979;25: 358-71.
20. Staahl C, Olesen AE, Andresen T, Arendt-Nielsen L, Drewes AM. Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review. Br J Clin Pharmacol 2009;68:149-68.
21. Koltzenburg M, Pokorny R, Gasser UE, Richarz U. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 2006;3:165-74.
22. Cavero I. Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society. Expert Opin Drug Saf 2007;6:465-71.
23. Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ, Armstrong PJ. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg 1988;67:329-37.
24. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 1997;35:401-13.
25. Yassen A, Olofsen E, Romberg R, Sarton E, Danhof M, Dahan A. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 2006;104:1232-42.
26. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627-32.
27. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003;2(Suppl):S13-27.
28. Jensen ML, Sjogren P, Upton RN, Foster DJ, Bonde P, Graae C et al. Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers. Basic Clin Pharmacol Toxicol 2008;103:94-101.
29. Bouhassira D, Chitour D, Villanueva L, Le BD. Morphine and diffuse noxious inhibitory controls in the rat: effects of lesions of the rostral ventromedial medulla. Eur J Pharmacol 1993;3:207-15.
30. Le BD, Chitour D, Kraus E, Clot AM, Dickenson AH, Besson JM. The effect of systemic morphine upon diffuse noxious inhibitory controls (DNIC) in the rat: evidence for a lifting of certain descending inhibitory controls of dorsal horn convergent neurones. Brain Res 1981;2:257-74.
31. Willer JC, Le BD, De BT. Diffuse noxious inhibitory controls in man: involvement of an opioidergic link. Eur J Pharmacol 1990;2:347-55.
32. Arendt-Nielsen L, Curatolo M, Drewes A. Human experimental pain models in drug development: translational pain research. Curr Opin Investig Drugs 2007;8:41-53.
33. Negus SS, Vanderah TW, Brandt MR, Bilsky EJ, Becerra L, Borsook D. Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J Pharmacol Exp Ther 2006;319:507-14.
34. Liu M, Max MB, Robinovitz E, Gracely RH, Bennett GJ. The human capsaicin model of allodynia and hyperalgesia: sources of variability and methods for reduction. J Pain Symptom Manage 1998;16:10-20.
35. Scanlon GC, Wallace MS, Ispirescu JS, Schulteis G. Intradermal capsaicin causes dose-dependent pain, allodynia, and hyperalgesia in humans. J Investig Med 2006;54:238-44.
36. Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001;297:688-95.
37. Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995;272:505-10.
38. Pontani RB, Vadlamani NL, Misra AL. Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica 1985;15:287-97.
39. Yue H, Borenstein MR, Jansen SA, Raffa RB. Liquid chromatography-mass spectrometric analysis of buprenorphine and its N-dealkylated metabolite norbuprenorphine in rat brain tissue and plasma. J Pharmacol Toxicol Methods 2005;52:314-22.
40. Jensen ML, Foster D, Upton R, Grant C, Martinez A, Somogyi A. Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica 2007;37:441-57.